All Comparisons
BPC-157 vs KPV
Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.
BPC-157: CKPV: D
| Attribute | BPC-157 | KPV |
|---|---|---|
| Category | Healing & Recovery | Anti-Inflammatory / Immune |
| Evidence Rating | C — Phase I–II Clinical Trials | D — Preclinical |
| Clinical Status | Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway. | Preclinical. No formal clinical trials completed. Used in compounding pharmacy protocols. Removed from FDA Category 2 on April 15, 2026. |
| Mechanism | BPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and Akt-eNOS axis. It engages ERK1/2 signaling, activating c-Fos, c-Jun, and EGR-1 transcription factors... | KPV exerts anti-inflammatory effects through a mechanism distinct from the parent α-MSH hormone. Rather than acting through melanocortin receptors (which would trigger pigmentation), KPV is transported into cells via PepT1, a di/tripeptide transporter expressed on intestinal epithelial cells and imm... |
| Half-Life | ~15 min IV (animal data); oral activity persists 24+ hours | ~2 hours (SC); shorter oral due to GI degradation |
| Bioavailability | IM: 15-19% (rats), 45-51% (dogs); resistant to stomach acid degradation | — |
| Molecular Weight | ~1419.5 g/mol | ~342.4 g/mol |
| WADA Status | Prohibited | Not Listed |
| Dosing | 200–600 mcg/day SC; oral doses studied at 1–6 mg in clinical trials, Once daily (Subcutaneous (preferred), Intramuscular, or Oral) | Oral: 200-500 mcg/day; SC: 100-500 mcg/day; Topical: 0.01-0.1% preparation, 1-2 times daily (Oral (gut), Subcutaneous (systemic), Topical (skin)) |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | Not FDA-approved. Removed from Category 2 on April 15, 2026 after HHS Secretary Kennedy directed withdrawal of nominations. PCAC review scheduled July 23-24, 2026 to determine compounding eligibility. Previously prohibited from compounding under Category 2 since September 2023. WADA-banned. | Not FDA-approved. Removed from FDA Category 2 on April 15, 2026 after HHS Secretary Kennedy directed withdrawal of nominations. PCAC review scheduled July 23-24, 2026. Research chemical. |
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.